Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
- 1441.744
- -8.464-0.58%
Market Falls Thursday, Producer Inflation Grows, and Tech Pulls Back From Records | LiveStock
Editas Cut to Equal Weight by Wells Fargo Over Reni-cel Positioning
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock
Editas Medicine Analyst Ratings
Market Falls Wednesday, but Googles Chip Impresses | WST
The Analyst Landscape: 6 Takes On Sangamo Therapeutics
10 Health Care Stocks With Whale Alerts In Today's Session
Sangamo Therapeutics Analyst Ratings
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
CRISPR Therapeutics Analyst Ratings
Vertex Upgraded to Buy by Jefferies on Fundamentals, Pipeline
Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock
Beam Therapeutics Analyst Ratings
Vertex Reports Positive Long-term Data for Casgevy
Editas Medicine Presents Data From RUBY Trial At ASH 2024, Showing Reni-Cel Achieves 96% VOE-Free Rate, Sustained Increases In Hemoglobin And Fetal Hemoglobin, And Clinically Meaningful Pain And Function Improvements In Severe Sickle Cell Patients;...
CRISPR Therapeutics Highlights CTX112 Data At ASH 2024, Showcasing Potential Clinical Benefits In R/R CD19-Positive B-Cell Malignancies; Receives FDA RMAT Designation For Follicular And Marginal Zone Lymphomas, With Phase 1 Trial Expanding Into...
Monday Market Falls, Chinese Stocks Climb, Indices Rebalance | Live Stock
Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains
Agilent Technologies Analyst Ratings
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 19 Analysts